BROADCASTS.com

Every week, The American Journal of Managed Care\xae recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.\n\nThis week, the top managed care stories included, CMS allowing step therapy in Medicare Advantage plans in a bid to allow for drug price negotiation; larger practices with more resources, technology and care management processes have higher readmission rates than smaller practices; studies find that empagliflozin also reduces liver fat in patients with diabetes and nonalcoholic fatty liver disease.\n\nRead more about the stories in this podcast:\nCMS Will Allow Medicare Advantage Plans to Use Step Therapy to Negotiate Drug Prices: https://www.ajmc.com/newsroom/cms-will-allow-medicare-advantage-plans-to-use-step-therapy-to-negotiate-drug-prices\nCMS Approves Extra Payments for CAR T, Increases Other Payments in Final Rule: https://www.ajmc.com/newsroom/cms-approves-extra-payments-for-car-t-increases-other-payments-in-final-rule\nLarger Practices Spend More on, Have Higher Readmission Rates for Medicare Beneficiaries: https://www.ajmc.com/focus-of-the-week/larger-practices-spend-more-on-have-higher-readmission-rates-for-medicare-beneficiaries\nLiquid Biopsy Identifies Patients More Likely to Benefit From Immunotherapy in NSCLC: https://www.ajmc.com/newsroom/liquid-biopsy-identifies-patients-more-likely-to-benefit-from-immunotherapy-in-nsclc\nStudies Point to Empagliflozin as First Choice for Fatty Liver Disease in T2D: https://www.ajmc.com/newsroom/studies-point-to-empagliflozin-as-first-choice-for-fatty-liver-disease-in-t2d\nDiscussing Increased Prevalence of NAFLD and NASH, and the Current Lack of Treatments: https://www.ajmc.com/managed-care-cast/discussing-increased-prevalence-of-nafld-and-nash-and-the-current-lack-of-treatments